



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	287766	C BioActive
ARTG entry for	Medicine Listed	
Sponsor	FIT-BioCeuticals Limited	
Postal Address	Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102 Australia	
ARTG Start Date	11/04/2017	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . C BioActive

Product Type	Single Medicine Product	Effective Date	18/12/2019
---------------------	-------------------------	-----------------------	------------

Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Maintain/support collagen formation
- Maintain/support energy levels
- Maintain/support energy production
- Relieve weariness/tiredness/fatigue/feeling of weakness
- Maintain/support healthy immune system function
- Maintain/support immune system to fight illness
- Maintain/support absorption of dietary (state vitamin/mineral/nutrient)
- Maintain/support (state vitamin/mineral/nutrient) levels in the body
- Maintain/support nerve conduction
- Aid/assist/helps synthesis of neurotransmitters
- Maintain/support nervous system function
- Maintain/support sperm health
- Maintain/support wound healing

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to chronic fatigue syndrome.



Australian Government
Department of Health
Therapeutic Goods Administration

Product presentation must not imply or refer to infertility.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to serious immunological diseases.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Adults only.

Not recommended for use by pregnant and lactating women (or words to that effect).

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Jar/Can	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule

Components

1 . Formulation 1

Dosage Form Powder, oral

Route of Administration Oral

Visual Identification

Active Ingredients

ascorbic acid	367.27 mg/g
ascorbyl palmitate	18.18 mg/g
Equivalent: ascorbic acid	7.73 mg/g
calcium ascorbate dihydrate	151.29 mg/g
Equivalent: ascorbic acid	125 mg/g
Citrus bioflavonoids extract	10 mg/g
glutathione	4 mg/g
palm tocotrienols complex	4 mg/g
quercetin dihydrate	5 mg/g
rutoside	20 mg/g
zinc amino acid chelate	5 mg/g
Equivalent: zinc	1 mg/g

Other Ingredients (Excipients)

- citric acid
- colloidal anhydrous silica
- Flavour
- glycine
- sodium bicarbonate
- Stevia rebaudiana

Public Summary



Australian Government

Department of Health
Therapeutic Goods Administration

written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary